Drug Profile


Alternative Names: Neocarzinostatin; NSC 157365; NSC 69856

Latest Information Update: 11 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Kayaku
  • Class Antineoplastics; Cytostatic antibiotics; Enediynes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Bladder cancer; Leukaemia; Pancreatic cancer
  • No development reported Haematological malignancies

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 10 Apr 2003 No development reported - Preclinical for Haematological malignancies (myeloablation) in USA (unspecified route)
  • 02 Sep 1999 A clinical study in patients with liver cancer has been added to the therapeutic trials and adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top